Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference
March 08 2022 - 7:00AM
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage
precision medicine company that discovers, develops, and
commercializes targeted therapeutics for patients with significant
unmet clinical need in immunology and rare genetic diseases,
announced today that members of its senior management team will
present at Oppenheimer's 32nd Annual Healthcare Conference on
Wednesday, March 16, 2022 at 1:20 p.m. ET.
A live webcast of the presentation can be
accessed under the "News/Events" page in the Investors section of
the Company's website at www.avalotx.com.
About Avalo Therapeutics
Avalo Therapeutics is a leading clinical-stage
precision medicine company that discovers, develops, and
commercializes targeted therapeutics for patients with significant
unmet clinical need in immunology and rare genetic diseases. The
Company has built a diverse portfolio of innovative therapies to
deliver meaningful medical impact for patients in urgent need. The
Company’s clinical candidates commonly have a proven mechanistic
rationale, biomarkers and/or an established proof-of-concept to
expedite and increase the probability of success.
For more information about Avalo, please visit
www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking
statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Avalo’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Avalo’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as “projects,” “may,” “might,” “will,”
“could,” “would,” “should,” “continue,” “seeks,” “aims,”
“predicts,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” or similar expressions (including
their use in the negative), or by discussions of future matters
such as: the future financial and operational outlook; the
development of product candidates or products; timing and success
of trial results and regulatory review; potential attributes and
benefits of product candidates; and other statements that are not
historical. These statements are based upon the current beliefs and
expectations of Avalo’s management but are subject to significant
risks and uncertainties, including: drug development costs, timing
and other risks, including reliance on investigators and enrollment
of patients in clinical trials, which might be slowed by the
COVID-19 pandemic; reliance on key personnel, including as a result
of recent management changes; regulatory risks; Avalo's cash
position and the potential need for it to raise additional capital;
general economic and market risks and uncertainties, including
those caused by the COVID-19 pandemic and tensions in Ukraine; and
those other risks detailed in Avalo’s filings with the SEC. Actual
results may differ from those set forth in the forward-looking
statements. Except as required by applicable law, Avalo expressly
disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Avalo’s expectations with respect
thereto or any change in events, conditions or circumstances on
which any statement is based.
For investor inquiries
Chris BrinzeyICR
Westwickechris.brinzey@westwicke.com339-970-2843
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Sep 2023 to Sep 2024